 I think the as always has something practice changing and this year it will be probably the kind of trial establishing there are a couple of the math decks as a new standard of care. There are other very interesting trial updates, for example for the Maya trial establishing there are some of my land a little my decks in front line treatment. They also establish always trends here we see a lot of discussion regarding the crud trubler treatment in front line so combining antibody proteasome inhibition immunomodulation and dexamethasone and it's the platform for the innovations. There is nothing really really new there is one very interesting by specific antibody construct which will be presented there are more consolidating data on car T cells there's now the immunocontogate which establishes it a bit more so we generate some substantial data and we generate also data to better understand why some treatments fail or why patients relapse or how can we keep more durability in response so I think we have in many aspects and on many levels very interesting data we see here it will be the huge taste retries which directly translate in approval like the derivative of capitalism of decks that will be confirming data for example for the pomalidomide border them at decks combination so that was what is presented here translates to Europe although we have a different situation but also the European authorities the boards everyone the physicians everyone is looking overseas at the time of us we are working so close that I would think that we directly can translate what we see here in our daily practice when we return